fbpx

ABOUT VHIO

VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer:

DISCOVER MORE

PROGRAMS & GROUPS

Scientific activity at VHIO is structured across for major programs: Preclinical, Translational, Clinical Research, and Core Technologies. Each incorporates research teams of excellence dedicated to harnessing and rapidly translating discoveries into tangible benefits for patients.

MEET VHIO´S TEAMS

NEWS

Cemiplimab steps up as the first immune-based therapy to improve overall survival in patients with recurrent and/or metastatic cervical cancer

12/05/2021|Comments Off on Cemiplimab steps up as the first immune-based therapy to improve overall survival in patients with recurrent and/or metastatic cervical cancer

Launched: VHIO’s Scientific Report 2020. A year of challenges, opportunities and hope

11/05/2021|Comments Off on Launched: VHIO’s Scientific Report 2020. A year of challenges, opportunities and hope

  • Dr Teresa Macarulla

VHIO is participating prominently in a study that seeks to evaluate the efficacy of a novel combination therapy in advanced pancreatic cancer

11/05/2021|Comments Off on VHIO is participating prominently in a study that seeks to evaluate the efficacy of a novel combination therapy in advanced pancreatic cancer

Special VHIO-CaixaResearch Scientific Seminar: VHIO Meet the Editors with Miguel Foronda, Associate Editor, Nature Cancer

04/05/2021|Comments Off on Special VHIO-CaixaResearch Scientific Seminar: VHIO Meet the Editors with Miguel Foronda, Associate Editor, Nature Cancer

Novel anti-PD-1 therapy, dostarlimab, approved as a new therapeutic avenue for recurrent or advanced endometrial cancer in Europe

04/05/2021|Comments Off on Novel anti-PD-1 therapy, dostarlimab, approved as a new therapeutic avenue for recurrent or advanced endometrial cancer in Europe

The combination of immunotherapy and targeted therapies does not improve outcomes in previously treated advanced urothelial cancer

04/05/2021|Comments Off on The combination of immunotherapy and targeted therapies does not improve outcomes in previously treated advanced urothelial cancer

SEE ALL NEWS

Follow us:

DIRECTION &
PRINCIPAL INVESTIGATORS

Research at VHIO is led by our Director, Josep Tabernero, and supported by a consultative body, VHIO’s Scientific Committee. A total of 26 renowned Principal Investigators manage and run VHIO’s major research themes and programs.

BROWSE OUR PIS

SCIENTIFIC
REPORT
2020

LAUNCH

CLINICAL TRIALS

Driving drug development & targeted therapies against cancer, VHIO has become a leading reference in drug discovery from concept to clinic:

CLINICAL TRIALS OFFICE
RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER (UITM) – CAIXARESEARCH
CURRENTLY OPEN TRIALS

PROJECTS & INSTITUTIONAL PROGRAMS

Research at VHIO is made possible through the support received from private institutions, funding entities, companies and individuals, as well as International and National Competitive Grants. Find out more about our supporters, current projects and VHIO´s Scientific Coordination Area:

CURRENT PROJECTS
FERO FOUNDATION’S ADVANCED MOLECULAR DIAGNOSTICS PROGRAM
BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI)
“LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM
SCIENTIFIC COORDINATION

EVENTS

VHIO organizes symposia of excellence and ad-hoc courses & workshops through which it shares its expertise and promotes debate and exchange of the highest degree:

VHIO – ”LA CAIXA” SCIENTIFIC SEMINARS SERIES
INTERNATIONAL SYMPOSIA
WORKSHOPS & COURSES
BENCHSTORMING SEMINARS